This communication is aimed specifically at exploring the possible practical advantages and potentials of 18-fluoro-deoxyglucose (FDG)–PET/ computed tomography (CT) that could translate into routine management of patients with infection and aseptic inflammatory disorders. From viewpoint of patient management, the applications can be classified into two broad categories, based upon primary intent of the investigation: [a] Diagnostic (eg, pyrexia of unknown origin and other localized infectious processes) and [b] Undertaking this as part of objective imaging assessment of early treatment response and thereby tailoring/altering therapy (eg, systemic infectious and non-infectious inflammatory diseases). Over the last decade, this promising FDG-PET/CT application has been debated and there is need to make systematic approach for defining its value to patient management.